These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10841002)

  • 1. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
    Owens DR; Coates PA; Luzio SD; Tinbergen JP; Kurzhals R
    Diabetes Care; 2000 Jun; 23(6):813-9. PubMed ID: 10841002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD; Beck P; Owens DR
    Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
    Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
    Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
    Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
    Scholtz HE; Pretorius SG; Wessels DH; Becker RH
    Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
    Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
    Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs.
    Jørgensen KH; Hansen AK; Buschard K
    Diabetes Res Clin Pract; 2000 Dec; 50(3):161-7. PubMed ID: 11106830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
    Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
    Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption kinetics of regular, isophane, and protamine zinc insulin in normal cats.
    Wallace MS; Peterson ME; Nichols CE
    Domest Anim Endocrinol; 1990 Oct; 7(4):509-15. PubMed ID: 2261761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine.
    Gerich J; Becker RH; Zhu R; Bolli GB
    Diabetes Technol Ther; 2006 Apr; 8(2):237-43. PubMed ID: 16734552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
    Yeldandi RR; Lurie A; Baldwin D
    Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption kinetics of regular and isophane (NPH) insulin in the normal dog.
    Goeders LA; Esposito LA; Peterson ME
    Domest Anim Endocrinol; 1987 Jan; 4(1):43-50. PubMed ID: 3333933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.
    Rave K; Nosek L; Heinemann L; Frick A; Becker R
    Diabetes Metab; 2003 Sep; 29(4 Pt 1):430-1. PubMed ID: 14526272
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
    Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin glargine: an updated review of its use in the management of diabetes mellitus.
    Dunn CJ; Plosker GL; Keating GM; McKeage K; Scott LJ
    Drugs; 2003; 63(16):1743-78. PubMed ID: 12904090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
    Luzio S; Dunseath G; Peter R; Pauvaday V; Owens DR
    Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucodynamics and pharmacokinetics of 70/30 vs. 50/50 NPH/regular insulin mixtures after subcutaneous injection.
    Krug EI; DeRiso L; Tedesco MB; Rao H; Korytkowski MT
    Diabetes Care; 2001 Sep; 24(9):1694-5. PubMed ID: 11522727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.